This will change your mind about Biohacking and Psychedelics

In this week's Dealmaker Show Interview, Oren will talk to Doug Drysdale on Biohacking and Psychedelics.

Doug Drysdale has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 13 years has built and turned around four pharmaceutical companies.

During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, and has raised $4 billion of both public and private capital.

Previously, Doug served as Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including over 25 banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.

Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012.